Skip to content
zynerba logo
  • Investors
    • IR Information
    • Stock Information
    • Press Releases
    • Events & Webcasts
    • Presentations
    • Enhanced SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Investor FAQs
    • IRS Form 8937
    • Investor Contacts
  • News
    • Press Releases
    • Events
  • Publications
    • Manuscripts and Presentations
  • Careers
  • LinkedIn
  • Twitter
  • Our Focus
    • Why Rare?
    • Why Neuropsychiatric Disorders?
    • Why Cannabinoids?
    • Why pharmaceutical manufacturing?
  • Our Pipeline
    • ZygelTM
    • Early Access to Medicine
  • Clinical Trials
  • Our Team
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Patient Resources
    • FXS
    • ASD
    • 22q
    • DEE
    • Epilepsy

Zynerba Press Releases

4 Aug 15 Zynerba Pharmaceuticals Announces Pricing of Its Initial Public Offering

30 Jun 15 Zynerba Files Registration Statement for Proposed Initial Public Offering of Common Stock

5 Jan 15 Zynerba Pharmaceuticals Appoints Richard A. Baron VP and CFO

26 Nov 14 Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014

19 Nov 14 Zynerba Pharmaceuticals to Present at Oppenheimer 25th Annual Healthcare Conference

15 Oct 14 Zynerba Pharmaceuticals Raises $13 Million to Develop First and Only Transdermal Cannabinoid Therapies

1 Oct 14 Zynerba Pharmaceuticals Builds Management Team

1 Oct 14 Zynerba Pharmaceuticals Appoints New Leadership Team: Armando Anido Named Chairman and CEO, Terri Sebree Named President

Page 15 of 15 | « First‹ Previous11 12 13 14 15

    This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy Notice.

    • Privacy Policy
    • Terms of Use
    • Contact Us

    © 2021 Zynerba Pharmaceuticals, Inc. All rights reserved.

    zynerba inverted logo

    80 W. Lancaster Avenue, Suite 300
    Devon, PA 19333
    484.581.7505